Prior to that, Paul was Head of Diabetes for Pricing, Market Accessand Health Economics for EUCAN within Takeda Pharmaceuticals. In this role, Paul was responsible for leading the franchise including managing the launch of a new diabetes therapy, providing input into R&D for pipeline products and optimising in-market products. Paul was also a member of the Pricing, Market Access and Health Economics (PMAHE) management team, helping set the strategic direction of the PMAHE department.
During his time in Nycomed, Paul led the strategic pricing team responsible for global pricing decisions for Nycomed’s global brands. He was also a core member of the PMAHE integration team during the Takeda takeover, helping to design and implement the new PMAHE organisation within Takeda.
Preceding Nycomed, Paul was a pricing and market access consultant with IMS Consulting based in Cambridge, UK. Here, he managed numerous global pricing and market access projects across a variety of international clients, developing launch pricing strategies, creating payer value propositions & communications and managing market access reorganisations.
Paul holds a PhD in molecular biology from Edinburgh University and has a BSc Biology from Manchester University.
Graham’s industry experience includes GSK, start-up biotech companies and Ferring pharmaceuticals. During his time at Ferring Graham was Global Head of Market Access and Pricing taking responsibility for all market access activities from incorporation of payer value into clinical development programs through to development and implementation of the market access and pricing strategy for global product launches of both pharmaceutical and diagnostic products.
Graham’s consultancy experience was obtained within both IMS consulting (previously Cambridge Pharma) and Adelphi Values whereby he was responsible for global pricing and reimbursement projects ranging from strategic insights to global pharmaceutical companies; market access training to senior management and affiliates; development of biosimilar access strategies and EU pricing and reimbursement submissions; landscape assessments for pharmaceutical and diagnostics within the EU and US
Graham has worked across many therapeutic areas including Gastroenterology, Urology, Fertility, Oncology, Obstetrics, Infectious Diseases and Endocrinology. Graham has a Ph.D. in neuropharmacology from Durham University and an MBA from Aston University.
Our Team Members
Charlie has experience across a range of different project types, including in-depth market analysis through primary and secondary research, payer advisory boards, forecasting models, value propositions, commercial messaging development and literature reviews. Charlie has worked across therapy areas that include several oncology indications, autoimmune disease, infectious disease, Alzheimer’s disease and oral contraceptives. Charlie also has experience in biosimilars, and in developing brand protection strategies for mature brands.
Charlie has an MSc in Biomaterials and Tissue Engineering from University College London, and a BSc in Biological Sciences from the University of Warwick.
Creating branded images, charts and infographics that effectively communicate key messages to be incorporated into presentations, workshop materials and market access training aids is one of Sarah’s key capabilities. Using her design techniques, Sarah creates and delivers visually powerful, interactive market access eLearning training programmes ensuring content is created to a high standard that adheres to company brand guidelines.
Sarah is also an expert in the use of EndNote referencing, PowerPoint and Word and provides internal training sessions to all Remap Consulting employees.
Prior to joining Remap Consulting, Sarah’s experience has been gained at Adelphi Values and AstraZeneca providing support for a variety of projects across various therapy areas.
Sarah also holds an ISEB qualification in Programme & Project Support Office and an accreditation in Articulate Storyline 2.
Fatima gained market access consultancy experience during her time at McCann Health, where she used her analytical skills to produce pricing and reimbursement landscape summaries, strategic recommendation reports and global value dossiers. Fatima’s scientific background and business acumen also enabled her to successfully complete disease opportunity assessments and develop strong value propositions for top pharmaceutical clients.
Fatima has worked on projects covering the marketing and regulatory aspects of drug development for a wide range of therapy areas, including oncology, diabetes and orphan diseases.
Fatima has a BSc in Biomedical Sciences from Manchester University.